NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) and Indivior (OTCMKTS:INVVY – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability and risk.
Analyst Ratings
This is a breakdown of recent recommendations for NRx Pharmaceuticals and Indivior, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| NRx Pharmaceuticals | 2 | 0 | 5 | 0 | 2.43 |
| Indivior | 0 | 0 | 1 | 0 | 3.00 |
NRx Pharmaceuticals presently has a consensus price target of $34.50, suggesting a potential upside of 1,038.61%. Indivior has a consensus price target of $50.00, suggesting a potential upside of 128.88%. Given NRx Pharmaceuticals’ higher probable upside, equities research analysts clearly believe NRx Pharmaceuticals is more favorable than Indivior.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| NRx Pharmaceuticals | $1.23 million | 106.67 | -$28.62 million | ($0.55) | -5.51 |
| Indivior | $791.00 million | 3.81 | $205.00 million | $1.05 | 20.81 |
Indivior has higher revenue and earnings than NRx Pharmaceuticals. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares NRx Pharmaceuticals and Indivior’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| NRx Pharmaceuticals | -691.81% | N/A | -63.92% |
| Indivior | N/A | N/A | N/A |
Volatility and Risk
NRx Pharmaceuticals has a beta of 2.19, meaning that its share price is 119% more volatile than the S&P 500. Comparatively, Indivior has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500.
Institutional & Insider Ownership
4.3% of NRx Pharmaceuticals shares are held by institutional investors. Comparatively, 0.1% of Indivior shares are held by institutional investors. 6.4% of NRx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Indivior beats NRx Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
About NRx Pharmaceuticals
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.
About Indivior
Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in Slough, the United Kingdom.
Receive News & Ratings for NRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
